First Patients Enrolled and Dosed in the Pivotal Trial of Phase 3 of the Immunotherapy Tedopi® for Advanced Non-Small Cell Lung Cancer
Paris, February 22nd, 2016, 6:30pm – OSE Pharma SA (ISIN: FR0012127173; Mnémo: OSE), an immunooncology company with a specific immunotherapy…